To the full analysis
Buyback calculator for Teva Pharmaceutical Industries
Teva Pharmaceutical Industries stock: key metrics
TEVATeva Pharmaceutical Industries had an operating margin of 12.5% and a return on invested capital (ROIC) of 10.2% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2006 | 50.7% | 9.5% | 6.5% |
| 2007 | 51.8% | 25.5% | 20.7% |
| 2008 | 53.8% | 10.3% | 5.7% |
| 2009 | 53.0% | 17.3% | 14.4% |
| 2010 | 56.2% | 24.0% | 20.7% |
| 2011 | 52.0% | 17.0% | 15.1% |
| 2012 | 52.4% | 10.9% | 9.7% |
| 2013 | 52.7% | 8.1% | 6.2% |
| 2014 | 54.5% | 19.5% | 15.1% |
| 2015 | 57.8% | 17.1% | 8.1% |
| 2016 | 54.1% | 9.8% | 1.5% |
| 2017 | 48.4% | −78.1% | −72.7% |
| 2018 | 44.0% | −8.7% | −11.4% |
| 2019 | 44.6% | −2.6% | −5.9% |
| 2020 | 46.4% | −21.4% | −24.0% |
| 2021 | 47.8% | 10.8% | 2.6% |
| 2022 | 46.7% | −14.7% | −16.4% |
| 2023 | 48.2% | 2.7% | −3.5% |
| 2024 | 48.7% | −1.8% | −9.9% |
| 2025 | 51.8% | 12.5% | 8.2% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2006 | 4.9% | 4.3% | 2.7% |
| 2007 | 14.2% | 13.0% | 8.3% |
| 2008 | 3.9% | 4.6% | 1.9% |
| 2009 | 10.4% | 9.6% | 5.9% |
| 2010 | 15.2% | 14.4% | 8.5% |
| 2011 | 12.4% | 9.6% | 5.5% |
| 2012 | 8.6% | 6.3% | 3.9% |
| 2013 | 5.6% | 4.8% | 2.7% |
| 2014 | 13.1% | 10.1% | 6.6% |
| 2015 | 5.3% | 7.6% | 2.9% |
| 2016 | 1.0% | 2.1% | 0.4% |
| 2017 | −93.7% | −23.0% | −23.0% |
| 2018 | −14.6% | −2.8% | −3.5% |
| 2019 | −7.2% | −0.8% | −1.7% |
| 2020 | −39.8% | −7.5% | −7.9% |
| 2021 | 4.1% | 3.5% | 0.9% |
| 2022 | −31.3% | −5.8% | −5.6% |
| 2023 | −7.4% | 1.3% | −1.3% |
| 2024 | −30.5% | −1.1% | −4.2% |
| 2025 | 17.8% | 10.2% | 3.5% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 7 Nov 2025)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.